Reading the annual reports…
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
First time this company is opened: we are analysing its official reports. This can take up to a minute; after that the page loads instantly.
PRGO · NYSE · United States · Pharmaceutical Preparations
In shortPERRIGO Co plc is loss-making, generates cash and carries moderate debt, with revenue shrinking (−2.8% last year).
Financial health
Weak
Built from five areas over the last five annual reports. Tap an area to see the figures behind it.
| Operating marginShare of each sale left after running the business, before interest and tax. | -26.4% | 0/100 |
|---|---|---|
| Net marginShare of each sale left as profit after every cost, interest and tax. | -33.5% | 0/100 |
| Return on equityProfit earned on the money shareholders put in. Above 15% is strong. | -39.3% | 0/100 |
| Return on invested capitalProfit earned on all the capital used (equity and debt). Above 10% usually means a real competitive edge. | -13.5% | 0/100 |
Weight in the score: 25%
| Current ratioShort-term assets divided by short-term debts. Below 1 can mean tight cash. | 2.76× | 100/100 |
|---|---|---|
| Debt / equityDebt compared with the shareholders' stake. Above 2 is heavily indebted. | 1.24× | 42/100 |
| Net debt / EBITDAYears of operating profit needed to repay net debt. Below 2 is comfortable. | – | n/a |
| Interest coverageHow many times operating profit covers interest. Below 2 is risky. | – | n/a |
| Altman Z''Bankruptcy-risk model. Above 2.6 safe, below 1.1 distress. | -0.37 | 0/100 |
Weight in the score: 25%
| Free cash flow marginCash left from each sale after investments. The money that can pay dividends or reduce debt. | 3.4% | 34/100 |
|---|---|---|
| Free cash flow / net incomeHow much accounting profit turns into real cash. Near 1 or above is healthy. | – | n/a |
| Years with positive free cash flow (last 5) | 5 of 5 | 100/100 |
Weight in the score: 20%
| Profitable years (last 5) | 0 of 5 | 0/100 |
|---|---|---|
| Years of revenue decline (last 5) | 2 of 5 | 33/100 |
| Revenue growth volatility | 5.5% | 91/100 |
| Operating margin volatility | 14.1% | 0/100 |
Weight in the score: 20%
| Revenue growth, 3-year average | -1.5% | 8/100 |
|---|---|---|
| EPS growth, 3-year average | – | n/a |
Weight in the score: 10%
Fiscal year 2025 · change vs prior year
Annual figures as reported. Hover a bar or point for the exact value.
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 5 fiscal years from the company's annual reports.
USD millions; negative values in parentheses.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | 4,139 | 4,452 | 4,656 | 4,373 | 4,253 |
| Cost of revenue | 2,723 | 2,996 | 2,975 | 2,831 | 2,759 |
| Gross profit | 1,416 | 1,455 | 1,680 | 1,543 | 1,495 |
| Research & development | 122 | 123 | 123 | 112 | 95 |
| Operating income | 410 | 79 | 152 | 113 | (1,122) |
| Pre-tax income | 259 | (139) | (8.3) | (81) | (1,298) |
| Income tax | 390 | (8.2) | (3.9) | 80 | 104 |
| Net income | (69) | (141) | (13) | (172) | (1,425) |
| Diluted EPS | −$0.52 | −$1.04 | −$0.09 | −$1.25 | −$10.29 |
| Diluted shares (millions) | 134 | 135 | 135 | 137 | 139 |
5 older years available with the 10-year history. Essential plan, from €8.25/month →
The last 8 reported quarters (10-Q and 10-K filings), in USD millions. The fourth quarter is derived from the annual report.
The last 8 quarters of PERRIGO Co plc are included in the Investor plan. Try free for 7 days →
−0.37 Distress zone
Estimates bankruptcy risk from working capital, retained earnings, operating profit and equity. Above 2.6 is considered safe, below 1.1 signals distress.
4/9
Nine yes-or-no tests on profitability, debt, liquidity and efficiency versus the prior year. 7 to 9 is strong, 0 to 3 is weak.
All figures: SEC EDGAR. Ratios and scores are computed by Scorvest (see how it works). Information only, not investment advice. How it works
Latest annual report: Jun 27, 2026 · Data updated Aug 5, 2026